HC Wainwright restated their buy rating on shares of Strongbridge Biopharma PLC (NASDAQ:SBBP) in a research report released on Wednesday. The brokerage currently has a $18.00 target price on the biotechnology company’s stock.

SBBP has been the topic of a number of other research reports. Oppenheimer Holdings, Inc. began coverage on Strongbridge Biopharma PLC in a report on Thursday, August 10th. They set an outperform rating and a $12.00 price objective on the stock. Zacks Investment Research upgraded Strongbridge Biopharma PLC from a sell rating to a hold rating and set a $7.25 target price on the stock in a research report on Wednesday, October 11th. Finally, ValuEngine downgraded Strongbridge Biopharma PLC from a hold rating to a sell rating in a research report on Monday, October 2nd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. The company presently has an average rating of Hold and a consensus price target of $11.81.

Strongbridge Biopharma PLC (NASDAQ SBBP) opened at $5.65 on Wednesday. Strongbridge Biopharma PLC has a twelve month low of $2.00 and a twelve month high of $8.85. The company has a quick ratio of 4.46, a current ratio of 4.70 and a debt-to-equity ratio of -1.89.

COPYRIGHT VIOLATION WARNING: This story was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/11/19/strongbridge-biopharma-plc-sbbp-rating-reiterated-by-hc-wainwright.html.

Several large investors have recently modified their holdings of SBBP. State of Wisconsin Investment Board purchased a new stake in shares of Strongbridge Biopharma PLC in the second quarter valued at $114,000. Rhumbline Advisers acquired a new position in Strongbridge Biopharma PLC in the second quarter valued at $154,000. California State Teachers Retirement System acquired a new position in Strongbridge Biopharma PLC in the second quarter valued at $277,000. Teachers Advisors LLC acquired a new position in Strongbridge Biopharma PLC in the second quarter valued at $297,000. Finally, Bank of New York Mellon Corp acquired a new position in Strongbridge Biopharma PLC in the second quarter valued at $331,000. Institutional investors and hedge funds own 56.53% of the company’s stock.

Strongbridge Biopharma PLC Company Profile

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.

Receive News & Stock Ratings for Strongbridge Biopharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma PLC and related stocks with our FREE daily email newsletter.